Precision BioSciences, Inc. (NASDAQ:DTIL) Holdings Reduced by Perceptive Advisors LLC

Perceptive Advisors LLC lessened its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 11.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 426,293 shares of the company’s stock after selling 54,190 shares during the period. Perceptive Advisors LLC owned 0.06% of Precision BioSciences worth $4,148,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Janus Henderson Group PLC acquired a new stake in Precision BioSciences in the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a report on Thursday, August 22nd.

Precision BioSciences Stock Performance

Precision BioSciences stock opened at $9.05 on Monday. The firm has a market cap of $62.68 million, a price-to-earnings ratio of -1.21 and a beta of 1.70. Precision BioSciences, Inc. has a 1 year low of $8.25 and a 1 year high of $19.43. The firm’s 50 day moving average price is $9.62 and its two-hundred day moving average price is $10.84.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Thursday, August 1st. The company reported $3.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $4.23. Precision BioSciences had a negative return on equity of 7.64% and a net margin of 19.36%. The business had revenue of $49.90 million for the quarter, compared to analysts’ expectations of $8.50 million. During the same period in the previous year, the firm posted ($3.00) EPS. As a group, equities analysts predict that Precision BioSciences, Inc. will post 0.82 EPS for the current fiscal year.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.